Meliha Kapetanovic, Randeep Mandla, Susanne Thiesen Gren, Maria Seddighzadeh, Dan Henrohn, Maaria Palmroth, Anna-Maria Hiltunen, Jussi Ranta, Anna-Kaisa Asikainen, Anne Grete Frøstrup, Veli-Jukka Anttila
{"title":"Vaccine Knowledge and Awareness Among Patients With Chronic Inflammatory Diseases: Results From a Nordic Survey.","authors":"Meliha Kapetanovic, Randeep Mandla, Susanne Thiesen Gren, Maria Seddighzadeh, Dan Henrohn, Maaria Palmroth, Anna-Maria Hiltunen, Jussi Ranta, Anna-Kaisa Asikainen, Anne Grete Frøstrup, Veli-Jukka Anttila","doi":"10.1177/23743735251360485","DOIUrl":null,"url":null,"abstract":"<p><p>A survey on vaccinations was conducted among patients with chronic inflammatory diseases (CIDs), including inflammatory bowel disease, inflammatory rheumatological diseases, and dermatological diseases (DDs). The objective was to identify differences between established vaccination guidelines and actual practices in healthcare as experienced by patients. Among eligible responders (<i>n</i> = 1434), 57% were on immunomodulatory treatment, and 59% were treated in specialized care. The most recommended vaccines were COVID-19 (66%), influenza (63%), and pneumococcal (46%). Regarding common vaccination principles for patients with CID, 61% reported not receiving information on vaccinations before treatment initiation. Only 23% were advised to check their vaccination status before starting medications, and just 20% reported that their vaccination status is regularly assessed. Logistic regression revealed that the DD group was less likely, while patients over 65 years of age or on immunomodulatory treatment were more likely to be recommended and receive vaccinations. Ideally, all CID patients should be eligible for preventive immunization starting from the time of diagnosis. A targeted vaccination program with clear responsibilities across the healthcare system is strongly recommended.</p>","PeriodicalId":45073,"journal":{"name":"Journal of Patient Experience","volume":"12 ","pages":"23743735251360485"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301179/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Patient Experience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23743735251360485","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
A survey on vaccinations was conducted among patients with chronic inflammatory diseases (CIDs), including inflammatory bowel disease, inflammatory rheumatological diseases, and dermatological diseases (DDs). The objective was to identify differences between established vaccination guidelines and actual practices in healthcare as experienced by patients. Among eligible responders (n = 1434), 57% were on immunomodulatory treatment, and 59% were treated in specialized care. The most recommended vaccines were COVID-19 (66%), influenza (63%), and pneumococcal (46%). Regarding common vaccination principles for patients with CID, 61% reported not receiving information on vaccinations before treatment initiation. Only 23% were advised to check their vaccination status before starting medications, and just 20% reported that their vaccination status is regularly assessed. Logistic regression revealed that the DD group was less likely, while patients over 65 years of age or on immunomodulatory treatment were more likely to be recommended and receive vaccinations. Ideally, all CID patients should be eligible for preventive immunization starting from the time of diagnosis. A targeted vaccination program with clear responsibilities across the healthcare system is strongly recommended.